Stoke Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held on June 3, 2025. Stoke Therapeutics, Inc. (STOK) is a Delaware corporation incorporated in 2017, with principal executive offices in Bedford, Massachusetts. The filing details the outcomes of four proposals submitted to security holders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Voting Results
The following proposals were adopted by stockholders:
- Election of Directors: Three Class III directors were elected to three-year terms expiring in 2028: Edward M. Kaye, M.D., Seth L. Harrison, M.D., and Arthur O. Tzianabos, Ph.D. All nominees received significant support with over 29 million shares voted "For" each.
- Ratification of Auditors: KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 38,678,091 shares voted "For" versus 67,754 "Against".
- Executive Compensation (Say-on-Pay): Stockholders approved, on a non-binding advisory basis, the compensation of named executive officers. 30,543,514 shares voted "For" compared to 2,882,907 "Against".
- Frequency of Say-on-Pay Votes: Stockholders approved holding future advisory votes on executive compensation every one year. 33,069,622 shares voted for the annual frequency.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a standard disclosure of voting results and contains no forward-looking financial statements or risk updates.
Investor Verification Checklist
- Verify the total number of shares outstanding and the percentage of votes cast for each director nominee to assess board support levels.
- Confirm the specific terms of the engagement with KPMG LLP for the 2025 fiscal year.
- Review the definitive proxy statement filed on April 22, 2025, for detailed executive compensation data referenced in the Say-on-Pay vote.
- Monitor future filings for the company's financial results, as this 8-K contains no financial metrics.